Andrew Maleki
Fortune : 19 533 $ au 30/09/2026
Fortune : 19 533 $ au 30/09/2026
Andrew Maleki is Chief Financial Officer at Surrozen, Inc. since 2025.
Mr. Maleki was Head-Corporate Development at Lassen Therapeutics, Inc. from 2021 to 2025.
Mr. Maleki completed undergraduate studies at Yale University and earned an MBA from Harvard Business School.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SURROZEN INC 0,01 % | 15/06/2026 | 607 ( 0,01 % ) | 19 533 $ | 30/09/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| SURROZEN, INC. | Directeur Financier/CFO | 12/11/2025 |
| Sociétés | Poste | Fin |
|---|---|---|
Lassen Therapeutics 1, Inc.
Lassen Therapeutics 1, Inc. BiotechnologyHealth Technology Develops novel and best-in-class biotherapeutics | Corporate Officer/Principal | 01/10/2025 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 4 |
|---|---|
Yale University
Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard Business School
Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lassen Therapeutics 1, Inc.
Lassen Therapeutics 1, Inc. BiotechnologyHealth Technology Develops novel and best-in-class biotherapeutics | Health Technology |
Surrozen, Inc.
Surrozen, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that discovering and developing drug candidates | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national